tbuckley/cabot-search huggingface dataset:
Abstract A26: Cancer-associated mutations impair the functional association of ETO/MTG family members with E proteins.
Authors: Pankaj Acharya, Scott W. Hiebert
Journal: Clinical Cancer Research (2015)

Abstract MTG8 and MTG16 are disrupted by the t(8;21) and t(16;21) chromosomal translocations respectively, yielding a fusion protein containing the N-terminal DNA-binding domain of RUNX1 fused to almost all of the MTG8 or MTG16. The t(8;21) is responsible for up to 15% of de novo AML cases, however, t(16;21) is relatively rare and has been liked to therapy-related AML. MTG16 is also disrupted by the inv(16)(p13.3q24.3) in 27% of non-Downs syndrome acute megakaryocytic leukemia (AMKL). This translocation fuses the first 3/4th of MTG16 to GLIS2. That two different ETO/MTG family members are disrupted by frequent translocations highlights the key regulatory role of this gene family, but we are just beginning to understand how ETO/MTG8 and MTG16/ETO2 act in transcriptional control and tumorigenesis. Proteomic studies suggest that these proteins link DNA binding proteins such as the “E proteins” E2A and HEB to the transcriptional machinery that controls RNA polymerase II transcriptional initiation and elongation. E-proteins also play a critical role in B- and T-cell development. Here, we have tested mutations uncovered by The Cancer Genome Atlas (TCGA) project in solid cancers that we predicted would affect the association between MTGs and E proteins. We found that the majority of these changes are silent in our assays but selected alterations impaired MTG-dependent interference with E2A-dependent transcriptional activation. This was also true in complementation assays in vivo. Furthermore, the mutations also affected E-protein-MTG interactions. These results suggest that inactivating mutations in MTG family members may contribute to solid cancers in specific instances, and also deregulate normal B- and T-cell development. Citation Format: Pankaj Acharya, Scott W. Hiebert. Cancer-associated mutations impair the functional association of ETO/MTG family members with E proteins. [abstract]. In: Proceedings of the AACR Special Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; Sep 20-23, 2014; Philadelphia, PA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(17 Suppl):Abstract nr A26.
Treatment of Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): An Analysis from the German Hodgkin Study Group (GHSG)
Authors: Dennis A. Eichenauer, Annette Pluetschow, Michael Fuchs, Karolin Behringer, Boris Böll, Bastian von Tresckow, Volker Diehl, Peter Borchmann, Andreas Engert
Journal: Blood (2014)
Open Access Platforms for Sharing Clinical Trial Data—Reply
Authors: Ann Marie Navar, Michael J. Pencina, Eric D. Peterson
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PET Screening for Metastatic Colorectal Adenocarcinoma
Authors: Michael S. Hofman, Robert E. Ware, Benjamin N. Thomson
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis
Authors: Sebastian Moran, Anna Martínez-Cardús, Sergi Sayols, Eva Musulén, Carme Balañá, Anna Estival-Gonzalez, Cátia Moutinho, Holger Heyn, Angel Diaz-Lagares, Manuel Castro de Moura, Giulia M Stella, Paolo M Comoglio, Maria Ruiz-Miró, Xavier Matias-Guiu, Roberto Pazo-Cid, Antonio Antón, Rafael Lopez-Lopez, Gemma Soler, Federico Longo, Isabel Guerra, Sara Fernandez, Yassen Assenov, Christoph Plass, Rafael Morales, Joan Carles, David Bowtell, Linda Mileshkin, Daniela Sia, Richard Tothill, Josep Tabernero, Josep M Llovet, Manel Esteller
Journal: The Lancet Oncology (2016)
BCL11A enhancer Haplotypes Are Associated with the Distribution of HbF in Arab-Indian and African Haplotype Sickle Cell Anemia but Not the Different Population Levels of HbF
Authors: Paola Sebastiani, John J. Farrell, Shuai Wang, Heather L Edward, Heather M. Shappell, Harold T. Bae, Clinton T. Baldwin, A. M. Al-Rubaish, Zaki Naserullah, Ahmed Alsuliman, Pradeep K. Patra, Lindsay A. Farrer, David H.K. Chui, Abdulrahman Alsultan, Duyen A. Ngo, Haifa Kathrin Al-Ali, Martin H. Steinberg
Journal: Blood (2014)
Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target
Authors: G Alatrash, H R Garber, M Zhang, P Sukhumalchandra, Y Qiu, H Jakher, A A Perakis, L Becker, S Y Yoo, K C Dwyer, K Coombes, A H Talukder, L S St John, V Senyukov, D A Lee, A Sergeeva, H He, Q Ma, P M Armistead, J Roszik, E A Mittendorf, J J Molldrem, D Hawke, G Lizee, S M Kornblau
Journal: Leukemia (2016)
Combination antimicrobial therapy in patients with Staphylococcus aureus bacteraemia—a post hoc analysis in 964 prospectively evaluated patients
Authors: S. Rieg, I. Joost, V. Weiß, G. Peyerl-Hoffmann, C. Schneider, M. Hellmich, H. Seifert, W.V. Kern, A. Kaasch
Journal: Clinical Microbiology and Infection (2016)
Intensification of Diabetes Therapy and Time Until A1C Goal Attainment Among Patients With Newly Diagnosed Type 2 Diabetes Who Fail Metformin Monotherapy Within a Large Integrated Health System
Authors: Kevin M. Pantalone, Brian J. Wells, Kevin M. Chagin, Flavia Ejzykowicz, Changhong Yu, Alex Milinovich, Janine M. Bauman, Michael W. Kattan, Swapnil Rajpathak, Robert S. Zimmerman
Journal: Diabetes Care (2016)

"Clinical inertia" has been used to describe the delay in the intensification of type 2 diabetes treatment among patients with poor glycemic control. Previous studies may have exaggerated the prevalence of clinical inertia by failing to adequately monitor drug dose changes and nonmedication interventions. This project evaluated the intensification of diabetes therapy and hemoglobin A1c (A1C) goal attainment among patients with newly diagnosed type 2 diabetes when metformin monotherapy failed.The electronic health record at Cleveland Clinic was used to identify patients with newly diagnosed type 2 diabetes between 2005 and 2013 who failed to reach the A1C goal after 3 months of metformin monotherapy. A time-dependent survival analysis was used to compare the time until A1C goal attainment in patients who received early intensification of therapy (within 6 months of metformin failure) or late intensification. The analysis was performed for A1C goals of 7% (n = 1,168), 7.5% (n = 679), and 8% (n = 429).Treatment was intensified early in 62%, 69%, and 72% of patients when poor glycemic control was defined as an A1C >7%, >7.5%, and >8%, respectively. The probability of undergoing an early intensification was greater the higher the A1C category. Time until A1C goal attainment was shorter among patients who received early intensification regardless of the A1C goal (all P < 0.05).A substantial number of patients with newly diagnosed type 2 diabetes fail to undergo intensification of therapy within 6 months of metformin monotherapy failure. Early intervention in patients when metformin monotherapy failed resulted in more rapid attainment of A1C goals.
Medicaid expansion is associated with improved access to care and self reported health, US study finds
Authors: Michael McCarthy
Journal: BMJ (2016)

Expansion of the US health insurance plan for those with limited financial resources, Medicaid, was associated with a significant increase in access to primary care services, lower out-of-pocket costs, and improvements in self reported health among low income residents in two states that had elected to expand the program, compared with those living in a state that had not, a new study found.1

Under the Affordable Care Act of 2010 states have been provided with funding to expand the eligibility of their Medicaid programs to allow access to anyone earning less than 138% of the federal poverty line, about $33 500 (£25 800; €30 000) …
Phase III trial of low-level laser therapy to prevent induced oral mucositis in head and neck cancer patients submitted to concurrent chemoradiation.
Authors: H. S. Antunes, D. Herchenhorn, C. M. Araujo, E. Cabral, E. M. d. S. Ferreira, I. A. Small, M. P. Rampini, N. Teich, P. C. Rodrigues, T. G. P. d. Silva, L. F. Dias, C. G. M. Ferreira
Journal: Journal of Clinical Oncology (2011)

LBA5524 Background: Oral mucositis (OM) remains a limiting factor in in head and neck squamous cell carcinomas (HNSCC) patients (pts) treated with chemoradiation (CRT) leading to pain, dysphagia, and weight loss. Low-level laser therapy (LLLT) emerges as a promising, preventive therapy of CRT-induced OM. Yet, a definitive randomized trial supporting its use is lacking. This study was designed to assess the efficacy of LLLT in reducing the incidence and/or severity of OM. Methods: Assuming OM grade (G3) for placebo 0.4 (P0); LLLT 0.15 (P 1 ) ; β=0.2; α=0.05, sample size was 94 pts. From Jun 2007 to Dec 2010, 47 LLLT and 47 placebo pts bearer of HNSCC of nasopharynx, oropharynx and hipopharynx entered a prospective, randomized, double blind, placebo-controlled, phase III trial. CRT consisted of conventional RT 70.2 Gy (1.8Gy/d, 5 times/wk) + concurrent cisplatin 100 mg/m 2 every 3 wks. Main endpoints were OM incidence and severity, RT interruptions due to OM and pain intensity. The LLLT used daily was a diode InGaAlP (660nm-100mW-4J/cm²). OM evaluation was done by WHO and OMAS scale. Results: Mean age was 54.6 and 87.2% of pts were male. Primary site: oropharynx (74 pts), nasopharynx (9 pts), hypopharynx (11 pts). In the LLLT arm the incidence of OM G 3/4 was only 6.4% versus 48% in the placebo arm; HR of 0.13 (IC 95%, p&lt;0.001). Besides in the LLLT arm 51% of pts did not have ulcers versus 17% in placebo arm (p&lt;0.001). LLLT pts had less severe pain (p=0.012), used less narcotic analgesic, HR 0.33 (IC 95%, p&lt;0.001) and required less gastrostomia, HR 0.037 (IC 95%, p= 0.005). No LLLT pts had RT interrupted due to OM. EORTC QLQ-C30 and its specific head and neck module QLQ-H&amp;N35 were applied. Results clearly favored the LLLT arm. In QLQ-C30 benefit was seen in both physical and emotional functioning (p=0.037), fatigue (p=0.011), pain (p=0.043); and in QLQ-H&amp;N35, pain (p=0.007), swallowing (p=0.001) and trouble with social eating (p=0.026). Conclusions: Our results indicate that upfront LLLT in HNSCC pts submitted to CRT is an effective tool in reducing G 3/4 OM, oral pain, use of narcotic and gastrostomia. QoL data supports the efficacy findings. Thereby LLLT should be the new standard of care in this setting.
Itch and systemic sclerosis: frequency, clinical characteristics and consequences
Authors: C. Théréné, E. Brenaut, H. Sonbol, E. Pasquier, A. Saraux, V. Devauchelle, E. Le Moigne, L. Misery, C. Abasq-Thomas
Journal: British Journal of Dermatology (2016)

Systemic sclerosis (SSc) is an autoimmune disease characterized by the excessive production of collagen (1). Itch is not usually considered to be a symptom of SSc. However, in a recent study, itch was a common symptom of SSc (42.6% of patients) (2). No study has yet examined the clinical features of itch in SSc.

This article is protected by copyright. All rights reserved.
hnRNP K: A Novel Regulator of Hematopoiesis and A Potential Predictive Biomarker In Acute Myeloid Leukemia
Authors: Miguel Gallardo, Hun Ju Lee, Xiaorui Zhang, Aziz Nazha, Laura R. Pageon, Steven M. Kornblau, Alfonso Quintás-Cardama, Sean M. Post
Journal: Blood (2013)
Informed Consent and the Reasonable-Patient Standard
Authors: Brian C. Drolet, Jonathan P. Brower
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PTH-002 Transanal endoscopic microsurgery: our experience with early rectal cancer
Authors: S J Dalton, O J Old, P G Vaughan-Shaw, M G Thomas
Journal: Gut (2010)

<h3>Introduction</h3> The use of transanal endoscopic microsurgery (TEMS) for the resection of benign rectal lesions is well established; its role in the management of carcinoma is less well defined. With the advent of the Bowel Cancer Screening Programme the incidence of early rectal cancer is increasing. Here we describe our experience of 25 cases undergoing TEMS resection for cancer. <h3>Methods</h3> An electronic database was used to identify the outcomes of patients undergoing TEMS procedures; operation and anaesthetic notes and original pathology reports were reviewed. Patients underwent TEMS if preoperative staging was limited to early uT1 disease or in more advanced disease where patients were not deemed fit for an anterior resection. <h3>Results</h3> 25 patients were included, (16 male 9 female), mean age was 69. ASA grade I,2; II,11 and III,12. Patients underwent preoperative staging with endoanal ultrasound and/or MRI. 20 patients were staged as uT1, four patients as uT2 and one patient as uT2/3 N1. In seven cases the lesion was located in the lower rectum and in 18 in the mid or upper third. Full thickness resections were performed in 22 patients with resection in the submucosal plane in three. Full thickness defects were closed in all cases. The mean size of specimen was 9 cm<sup>2</sup> (95% CI 3.5 to 14.5 cm<sup>2</sup>. Histopathology revealed that two patients had been understaged; both had pT2 N0 disease; one underwent anterior resection and one declined further surgery. All but two patients had R0 resections and one patient with a pT1 R0 resection developed recurrent disease. Mean operating time was 110 min (95% CI 92 to 128) and median length of stay was 3 days (range 2–15 days). Four patients had complications; two patients bled post-operatively, one requiring re-operation, one patient developed post-operative emphysema and one a recto-vaginal fistula. <h3>Conclusion</h3> Our series demonstrates that TEMS is a useful technique for the resection of uT1 disease though is not without complication. Where pT1 SM3 or more advanced disease is present anterior resection is advised.
Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer
Authors: Santosh Gupta, Jing Li, Gabor Kemeny, Rhonda L. Bitting, Joshua Beaver, Jason A. Somarelli, Kathryn E. Ware, Simon Gregory, Andrew J. Armstrong
Journal: Clinical Cancer Research (2016)

Abstract Purpose: Beyond enumeration, circulating tumor cells (CTCs) can provide genetic information from metastatic cancer that may facilitate a greater understanding of tumor biology and enable a precision medicine approach. Experimental Design: CTCs and paired leukocytes from men with metastatic castration-resistant prostate cancer (mCRPC) were isolated from blood through red cell lysis, CD45 depletion, and flow sorting based on EpCAM/CD45 expression. We next performed whole genomic copy number analysis of CTCs and matched patient leukocytes (germline) using array-based comparative genomic hybridization (aCGH) from 16 men with mCRPC, including longitudinal and sequential aCGH analyses of CTCs in the context of enzalutamide therapy. Results: All patients had mCRPC and primary or acquired resistance to abiraterone acetate or enzalutamide. We compiled copy gains and losses, with a particular focus on those genes highly implicated in mCRPC progression and previously validated as being aberrant in metastatic tissue samples and genomic studies of reference mCRPC datasets. Genomic gains in &amp;gt;25% of CTCs were observed in AR, FOXA1, ABL1, MET, ERG, CDK12, BRD4, and ZFHX3, while common genomic losses involved PTEN, ZFHX3, PDE4DIP, RAF1, and GATA2. Analysis of aCGH in a sample with sequential enzalutamide-resistant visceral progression showed acquired loss of AR amplification concurrent with gain of MYCN, consistent with evolution toward a neuroendocrine-like, AR-independent clone. Conclusions: Genomic analysis of pooled CTCs in men with mCRPC suggests a reproducible, but highly complex molecular profile that includes common aberrations in AR, ERG, c-MET, and PI3K signaling during mCRPC progression, which may be useful for predictive biomarker development. Clin Cancer Res; 23(5); 1346–57. ©2016 AACR.
Case 39-1969
Authors: Caesar Briefer, Benjamin Castleman
Journal: New England Journal of Medicine (1969)

Presentation of Case First admission. A sixty-seven-year-old man was admitted to the hospital because of pain in the ribs and back.He had been well until a year previously, when he had an episode of pain in the chest and on admission to another hospital was told that he had had a heart attack. He was well thereafter until four months before admission, when he began to experience continuous dull, aehing pain in the left anterior portion of the chest, with radiation down the inner aspect of the left arm. Three months later he entered another hospital; a digitalis preparation . . .
Chronic Myeloid Leukemia in Chronic Phase: Survival in the Era of Tyrosine Kinase Inhibitors Is Similar to That of the General Population in All Age Groups
Authors: Koji Sasaki, Sara S. Strom, Susan O'Brien, Elias Jabbour, Farhad Ravandi, Marina Konopleva, Gautam Borthakur, Naveen Pemmaraju, Naval Daver, Sherry R. Pierce, Hagop M. Kantarjian, Jorge E. Cortes
Journal: Blood (2014)
A first-in-human phase I dose-escalation study of MK-1496, first-in-class orally available novel PLK1 inhibitor, in patients with advanced solid tumors.
Authors: T. Doi, H. Murakami, K. Wan, M. Miki, H. Kotani, N. Sakamoto, N. Yamamoto, A. Ohtsu
Journal: Journal of Clinical Oncology (2011)

3012 Background: Polo-like kinase 1 (PLK1) is a serine/threonine kinase involved in cell cycle control, especially has key roles in multiple steps of mitosis progression. Overexpression of PLK1 is frequently observed in a range of human tumors, suggesting PLK1 function is important for proliferation of cancer cells. MK-1496 is an orally available highly potent and selective inhibitor of PLK1 with demonstrated anti-proliferative activity in vitro and in vivo. Methods: Sequential cohorts of 3 to 6 patients (pts) with progressive advanced or metastatic solid tumors received an MK-1496 dosing regimen of days 1 and 3 of each treatment wk for 3 wks followed by 1 wk rest period, following a toxicity guided dose escalation design. A total of 17 pts were treated at doses from 20 to 120 mg. Results: Reversible hematotoxicity was the main side effect constituting DLTs observed at 100 mg and 120 mg. The most frequent G3/4 adverse events were leukopenia (35%), neutropenia (35%), thrombocytopenia (29%), febrile neutropenia (18%) and anemia (18%). The MTD was determined as 80 mg. There was no evidence of cumulative toxicity. The PK profile was evaluated in 17 pts and demonstrated linearity in the dose range, a long t1/2 of around 25-47 hrs. Neutropenia caused by MK-1496 is a mechanism-based effect of PLK1 inhibition and can be used as a PD marker due to a trend of correlation with PK parameters. Two confirmed PRs were observed in pts with parotid gland carcinoma at 80 mg and small cell lung cancer at 120 mg. Conclusions: Preliminary results from this first-in-human trial confirm the favorable PK and safety profiles of the potentially first-in-class PLK1 inhibitor, MK-1496. Encouraging antitumor efficacy has been observed supporting PLK1 as a therapeutic target and further clinical development of this compound.
Highlights of the Year in JACC2009
Authors: Anthony N. DeMaria, Jeroen J. Bax, Ori Ben-Yehuda, Gregory K. Feld, Barry H. Greenberg, Jennifer Hall, Mark Hlatky, Wilbur Y.W. Lew, João A.C. Lima, Alan S. Maisel, Sanjiv M. Narayan, Steven Nissen, David J. Sahn, Sotirios Tsimikas
Journal: Journal of the American College of Cardiology (2010)
Fractionated 90y Ibritumomab Tiuxetan (Zevalin™) Radioimmunotherapy As An Initial Therapy of Follicular Lymphoma – First Results From a Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria
Authors: Timothy M Illidge, Ruth Pettengell, Michael Bayne, Steven Le Gouill, Andrew Bates, John Radford, Jill Tipping, Maureen Zivanovic, Françoise kraeber-Bodere, Emmanuel Malek, Huglo Damien, Franck Morschhauser
Journal: Blood (2011)
Glucose Levels Prior to Stem Cell Transplant Affect Length of Stay and 90-Day Readmission Rates
Authors: Amir Steinberg, Janet H Van Cleave, Douglas Marks, Molly Lawson, Antoinette Montelibano, Amanda Philpott, Kourtney Garner, Eric So, Deirdre Ali, Erin Moshier, Marisa Cortese, Marilyn Hammer
Journal: Blood (2015)